^
    2d
    BLOOM-ON: Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=102, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    5d
    A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
    New P2 trial
    |
    IL2 (Interleukin 2)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    6d
    PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    7d
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • Tagrisso (osimertinib) • carboplatin • Ivesa (firmonertinib)
    7d
    A Phase I Study of CS5007 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Not yet recruiting, CStone Pharmaceuticals
    New P1 trial • First-in-human
    9d
    A Phase I Study of JSKN021 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=199, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P1 trial • First-in-human
    13d
    Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=282, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • carboplatin • Tyvyt (sintilimab) • limertinib (ASK120067)
    13d
    A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors (clinicaltrials.gov)
    P1, N=155, Recruiting, NEOK Bio, Inc.
    New P1 trial • First-in-human
    14d
    Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) (clinicaltrials.gov)
    P2/3, N=500, Recruiting, Bristol-Myers Squibb | Trial completion date: May 2031 --> Nov 2030 | Trial primary completion date: Sep 2028 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • carboplatin • pemetrexed • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    19d
    Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. (clinicaltrials.gov)
    P2, N=252, Not yet recruiting, Shanghai Allink Biotherapeutics Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR expression • MET expression
    |
    Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    19d
    A Study of IDP-001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=132, Not yet recruiting, InduPro, Inc.
    New P1/2 trial